|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: ALPHAGAN P
Summary for Tradename: ALPHAGAN P
|
| |||||||||||
Clinical Trials for: ALPHAGAN PSafety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD) Status: Completed Condition: Macular Degeneration Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2% Status: Completed Condition: Erythematous Rosacea An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa Status: Completed Condition: Retinitis Pigmentosa Effect of Topical Brimonidine on Post Cataract Surgery Corneal Edema Status: Not yet recruiting Condition: Corneal Edema; Visual Acuity Three Month Efficacy/Safety Study With a 3 Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2% Status: Completed Condition: Open Angle Glaucoma; Ocular Hypertension Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2% Status: Completed Condition: Open-Angle Glaucoma; Ocular Hypertension Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy Status: Completed Condition: Vitrectomy Study to Determine if Taking OTC Non-Steroidal Anti-Inflammatory Affects Eye Pressure in Patients Using Glaucoma Drops Status: Completed Condition: Glaucoma; Ocular Hypertension Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension Status: Completed Condition: Glaucoma; Ocular Hypertension Effect of Brimonidine on Corneal Thickness Status: Recruiting Condition: Impact of Brimonidine on the Cornea Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allergan | ALPHAGAN P | brimonidine tartrate | SOLUTION/DROPS; OPHTHALMIC | 021262 | Mar 16, 2001 | RX | Yes | 5,424,078*PED | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Allergan | ALPHAGAN P | brimonidine tartrate | SOLUTION/DROPS; OPHTHALMIC | 021262 | Mar 16, 2001 | RX | Yes | 6,562,873*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Allergan | ALPHAGAN P | brimonidine tartrate | SOLUTION/DROPS; OPHTHALMIC | 021262 | Mar 16, 2001 | RX | Yes | 6,627,210*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Allergan | ALPHAGAN P | brimonidine tartrate | SOLUTION/DROPS; OPHTHALMIC | 021262 | Mar 16, 2001 | RX | Yes | 6,641,834*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Paragraph IV activity for: ALPHAGAN P
| Drugname | Dosage | Strength | RLD | Submissiondate |
| brimonidine tartrate | Ophthalmic Solution | 0.10% | Alphagan P | 12/20/2006 |
| brimonidine tartrate | Ophthalmic Solution | 0.15% | Alphagan P | 11/3/2006 |
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc